Two types of tumor-agnostic therapies seek reimbursement listing in Korea.

Industry sources say Roche Korea’s Neurotrophic tyrosine receptor kinase(NTRK) Rozlytrek (entrectinib) and Bayer Korea’s ‘Vitrakvi (larotrectinib)’ will be up for deliberation by the National Health Insurance Service's (NHIS) Cancer Drug Review Committee meeting on the 26th.

Rozlytrek and Vitrakvi are indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatm